Wiskott-Aldrich syndrome is a rare genetic condition that disrupts the immune system, causes bleeding problems, and leads to skin inflammation. Treatment focuses on preventing serious infections, managing bleeding complications, and ultimately correcting the underlying immune defect through advanced therapies.

How medical care helps children with Wiskott-Aldrich syndrome

When a child receives a diagnosis of Wiskott-Aldrich syndrome, the immediate focus shifts to protecting their health while planning for longer-term solutions. This rare condition affects primarily boys and creates multiple challenges that require careful medical attention. The main goals of treatment include preventing life-threatening infections, controlling bleeding episodes, managing uncomfortable skin conditions, and ultimately correcting the immune system defect that causes all these problems.^[1]

Treatment approaches depend heavily on how severe the disease is and which symptoms are causing the most trouble. Some children experience the full classic form of the disease, with serious immune problems, low platelet counts, and severe eczema. Others have milder versions called X-linked thrombocytopenia, where bleeding problems are the main concern but immune function remains relatively intact. Because the disease varies so much from person to person, doctors create individualized treatment plans based on each child’s specific needs and how their body responds to different therapies.^[3]

Medical societies and expert immunologists have established guidelines for managing Wiskott-Aldrich syndrome based on decades of experience treating affected children. These recommendations include both standard treatments that help manage symptoms and advanced therapies that can potentially cure the disease. At the same time, researchers continue studying new approaches in clinical trials, offering hope that future treatments will become even more effective and accessible for families dealing with this challenging condition.^[4]

Standard treatment approaches

For children with classic Wiskott-Aldrich syndrome, standard medical care begins with protecting them from infections while their immune system cannot function properly. Doctors typically prescribe prophylactic antibiotics, which are medications taken regularly to prevent infections before they start. One commonly used antibiotic is cotrimoxazole (also known as trimethoprim-sulfamethoxazole), given at a dose of 20 milligrams per kilogram of body weight daily. This medication specifically helps prevent a dangerous lung infection called Pneumocystis pneumonia, which can be life-threatening for children with weakened immune systems.^[12]

Another important preventive antibiotic is azithromycin, given at 10 milligrams per kilogram three times weekly. This medication provides broader protection against various bacterial infections that commonly affect children with Wiskott-Aldrich syndrome. For children who experience frequent viral infections, particularly those caused by herpes viruses, doctors may prescribe acyclovir for chronic suppression. These medications work by creating a protective shield, reducing the likelihood that bacteria or viruses will cause serious illness.^[12]

Immunoglobulin replacement therapy forms another cornerstone of standard treatment. This therapy involves regular infusions of antibodies collected from healthy blood donors. These antibodies, called immunoglobulins, help compensate for the defective immune response in children with Wiskott-Aldrich syndrome. The therapy can be given intravenously (directly into a vein) at a dose of 500 milligrams per kilogram every three to four weeks, or subcutaneously (under the skin) at 100 milligrams per kilogram weekly. The antibodies circulate through the bloodstream and help fight off infections that the child’s own immune system cannot handle effectively.^[12]

Managing the skin condition is equally important for maintaining quality of life. The eczema associated with Wiskott-Aldrich syndrome can be severe, causing intense itching, pain, and vulnerability to skin infections. Treatment typically involves careful attention to skin care, including regular use of moisturizing lotions called emollients that keep skin hydrated and create a protective barrier. When inflammation flares up, doctors prescribe topical corticosteroids — steroid creams or ointments applied directly to affected areas. These medications reduce inflammation and relieve itching. Because eczematous skin becomes easily infected, children may need systemic antibiotics when bacterial infections develop on damaged skin areas.^[12]

The bleeding problems caused by low and abnormal platelet counts sometimes require emergency treatment. When children experience severe bleeding episodes, doctors may administer high-dose intravenous immunoglobulin at 2 grams per kilogram of body weight. This high dose can temporarily boost platelet counts by reducing their destruction in the spleen. Corticosteroids like prednisolone at 2 milligrams per kilogram daily may also help increase platelet numbers. In cases of serious bleeding, children may need transfusions of platelets or red blood cells to replace what has been lost. These interventions can be lifesaving when bleeding occurs in critical areas like the brain.^[12]

Autoimmune complications affect between 40 and 70 percent of patients with Wiskott-Aldrich syndrome. These occur when the malfunctioning immune system mistakenly attacks the body’s own tissues. Common autoimmune problems include autoimmune cytopenias, where the immune system destroys blood cells, and conditions like vasculitis (inflammation of blood vessels) or arthritis (joint inflammation). These complications can be difficult to treat but may respond to a medication called rituximab, given as four weekly doses of 375 milligrams per square meter of body surface area, combined with prednisolone. Rituximab works by targeting and temporarily depleting certain immune cells that contribute to autoimmune attacks.^[12]

Children with Wiskott-Aldrich syndrome can receive killed (inactivated) vaccines, although their immune response may be insufficient due to their underlying immune dysfunction. However, live attenuated vaccines — which contain weakened but living versions of viruses — are strictly contraindicated because they could cause serious infections in these immunocompromised children. After exposure to chickenpox, children should receive high-dose immunoglobulin infusions that contain high levels of antibodies against the varicella virus, providing temporary protection.^[12]

These standard treatments help manage symptoms and prevent complications, but they do not cure the underlying genetic defect. Therefore, doctors simultaneously plan for definitive treatment — either stem cell transplantation or gene therapy — which offers the possibility of truly correcting the disease rather than just managing its symptoms.^[10]

Curative treatment through stem cell transplantation

Hematopoietic stem cell transplantation represents the standard of care for infants and young children with classic Wiskott-Aldrich syndrome. This procedure involves replacing the child’s defective bone marrow — which produces abnormal blood and immune cells — with healthy stem cells from a donor. When successful, the transplanted stem cells take up residence in the bone marrow and begin producing normal blood cells, including properly functioning immune cells and platelets. This effectively cures the disease because all new blood cells carry the healthy genetic information from the donor.^[12]

Many centers aim to perform stem cell transplantation early in life, ideally within the first two years, before serious complications from infection, bleeding, or autoimmune disease develop. The best outcomes occur when a perfectly matched donor is available — typically a sibling who shares the same tissue type. However, transplantation is also possible using matched unrelated donors found through bone marrow registries, or using umbilical cord blood from donors. The procedure requires careful preparation with chemotherapy drugs that suppress the child’s existing immune system and make room in the bone marrow for the donor cells to engraft.^[12]

The success rates for stem cell transplantation have improved dramatically over recent decades as doctors have refined their techniques. Transplants using matched sibling donors generally have the highest success rates. However, the procedure carries risks, including the possibility that the donor immune cells might attack the recipient’s body (graft-versus-host disease), or that the child might develop infections during the vulnerable period after transplant when the new immune system is still developing. Despite these risks, transplantation offers the best chance for long-term survival and normal quality of life for children with severe Wiskott-Aldrich syndrome.^[17]

For children who lack a matched donor, or for families who prefer alternatives to transplantation, gene therapy has emerged as a promising option. This approach avoids the risks associated with receiving cells from another person while still offering the possibility of cure.^[10]

Gene therapy: Treatment in clinical trials

Gene therapy for Wiskott-Aldrich syndrome represents one of the most promising advances in treating this condition. The concept is similar to stem cell transplantation, but instead of receiving healthy cells from a donor, the child receives their own cells that have been genetically corrected in the laboratory. This eliminates the risk of graft-versus-host disease and the need to find a matched donor, making curative treatment available to more children.^[13]

The gene therapy process begins by collecting hematopoietic stem cells from the patient’s bone marrow or bloodstream. These cells carry the genetic anomaly — mutations in the WAS gene — that causes all the symptoms of the disease. In the laboratory, scientists use a specially engineered lentiviral vector to introduce a healthy, functional copy of the WAS gene into these cells. The lentivirus acts as a delivery vehicle, efficiently inserting the correct genetic information into the stem cells’ DNA. Once corrected, these cells can produce normal amounts of the WAS protein, which is crucial for proper immune cell function.^[14]

After the genetic correction is complete, the patient receives chemotherapy to prepare their bone marrow, similar to the preparation for stem cell transplantation. The gene-corrected cells are then infused back into the patient’s bloodstream. These cells migrate to the bone marrow, where they engraft and begin producing various types of blood cells — white blood cells, red blood cells, and platelets — all now carrying the functional WAS gene. Over time, these corrected cells populate the entire blood and immune system, effectively curing the disease at its source.^[14]

Genethon, a French research organization, developed a lentiviral-based gene therapy product and sponsored two major international clinical trials. These Phase I/II trials took place at Necker-Enfants Malades hospital in Paris, France, and Great Ormond Street Hospital in London, United Kingdom. Another trial using vectors produced by Genethon was conducted at Children’s Hospital in Boston, United States. These early-phase trials focused on evaluating the safety of the treatment and gathering preliminary evidence about its effectiveness in patients with severe forms of Wiskott-Aldrich syndrome.^[7]

The trials began in 2011 and treated a total of ten patients across the European sites, with the last patient completing treatment in the third quarter of 2019. Trial participants are monitored extensively for ten years following treatment: two years in the main trial phase, followed by eight additional years in a long-term safety follow-up study. This extended monitoring is crucial for detecting any delayed complications and confirming the durability of the treatment’s benefits.^[7]

Results from these clinical trials have been extremely encouraging. In January 2022, researchers announced long-term efficacy data following eight patients for periods ranging from four to nine years after gene therapy treatment. The findings, published in the medical journal Nature Medicine, showed that gene-corrected cells engrafted stably in all patients. Importantly, there were no severe adverse effects directly related to the gene therapy treatment itself, confirming the safety profile of this approach.^[13]

Even more significantly, patients experienced substantial and sustained improvements in their clinical symptoms. The gene therapy led to significant reduction in severe eczema, with many children’s skin conditions improving dramatically. The frequency and severity of serious infections decreased markedly, as the corrected immune cells regained their ability to fight off bacteria, viruses, and fungi. Bleeding episodes became less frequent and less severe as platelet production improved, although the degree of improvement varied among individual patients. These clinical benefits remained stable over years of follow-up, suggesting that the treatment provides lasting correction rather than temporary improvement.^[7]

The trials in France and the United Kingdom formally ended in 2017 and 2019 respectively, but long-term safety monitoring continues. Seven patients remained under observation as part of the safety study, with the longest follow-up now exceeding nine years since treatment. Throughout this period, the benefits have persisted, and no concerning safety signals have emerged. This long-term data is particularly important because it demonstrates that the gene therapy provides durable correction of the immune defect.^[7]

Based on these promising results, Genethon obtained “Orphan drug” status from the European Medicines Agency (EMA) for this gene therapy product on July 10, 2013, under designation number EU/3/13/1196. This special regulatory status is granted to treatments for rare diseases and provides certain benefits that can help bring the therapy to wider availability more quickly.^[7]

The success of gene therapy depends on achieving stable engraftment of the corrected cells and maintaining long-term production of functional WAS protein. Research has shown that even partial correction — where some percentage of blood cells carry the functional gene — can provide significant clinical benefit. This is because the corrected cells have a survival advantage and can gradually expand within the body’s blood cell population over time. As more corrected cells accumulate, immune function improves progressively.^[13]

Clinical trial eligibility typically focused on patients with severe forms of Wiskott-Aldrich syndrome who lacked a matched sibling donor for traditional stem cell transplantation. This ensured that gene therapy trials enrolled patients who truly needed alternative curative options. Patients enrolled in European trials were treated at specialized centers with expertise in both primary immunodeficiency diseases and advanced cell therapy techniques, ensuring they received the highest level of care throughout the process.^[14]

While the gene therapy trials for Wiskott-Aldrich syndrome have shown remarkable success, this treatment remains experimental and is not yet widely available outside of clinical trial settings. Families interested in gene therapy should discuss with their child’s immunologist whether clinical trials are currently enrolling patients and whether their child might be eligible. As more long-term data accumulates and regulatory approvals are obtained, gene therapy may eventually become a standard treatment option alongside stem cell transplantation.^[7]

Most common treatment methods

• Prophylactic antibiotics
  • Cotrimoxazole given at 20 milligrams per kilogram daily to prevent Pneumocystis pneumonia
  • Azithromycin at 10 milligrams per kilogram three times weekly for broader bacterial infection prevention
  • Acyclovir for chronic suppression of herpes virus infections
• Immunoglobulin replacement therapy
  • Intravenous immunoglobulin (IVIG) at 500 milligrams per kilogram every three to four weeks
  • Subcutaneous immunoglobulin (SQIG) at 100 milligrams per kilogram weekly
  • High-dose IVIG (2 grams per kilogram) for severe bleeding episodes
• Skin care management
  • Regular application of emollients to maintain skin hydration
  • Topical corticosteroids for eczema flares
  • Systemic antibiotics for bacterial skin infections
• Bleeding management
  • Corticosteroids such as prednisolone at 2 milligrams per kilogram daily
  • Platelet transfusions for severe bleeding (all blood products must be irradiated)
  • Red blood cell transfusions when needed
• Autoimmunity treatment
  • Rituximab given as four weekly doses of 375 milligrams per square meter
  • Prednisolone combined with rituximab for autoimmune cytopenias
• Hematopoietic stem cell transplantation
  • Ideally performed within the first two years of life
  • Best results with matched sibling donors
  • Also possible with matched unrelated donors or cord blood
  • Requires chemotherapy preparation before transplant
• Gene therapy
  • Uses lentiviral vectors to introduce functional WAS gene into patient’s own stem cells
  • Trials conducted in France, United Kingdom, and United States
  • Shows stable engraftment and long-term efficacy with up to nine years of follow-up
  • Improves eczema, infections, and bleeding with no severe treatment-related adverse effects
  • Patients monitored for ten years after treatment